Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2016 Sep 1

PMID 27579037

Citations 49

Authors

Antonio Simone Lagana

Paola Rossetti

Massimo Buscema

Sandro La Vignera

Rosita Angela Condorelli

Giuseppe Gullo

Roberta Granese

Onofrio Triolo

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is characterized by chronical anovulation and hyperandrogenism which may be present in a different degree of severity. Insulin-resistance and hyperinsulinemia are the main physiopathological basis of this syndrome and the failure of inositol-mediated signaling may concur to them. Myo (MI) and D-chiro-inositol (DCI), the most studied inositol isoforms, are classified as insulin sensitizers. In form of glycans, DCI-phosphoglycan and MI-phosphoglycan control key enzymes were involved in glucose and lipid metabolism. In form of phosphoinositides, they play an important role as second messengers in several cellular biological functions. Considering the key role played by insulin-resistance and androgen excess in PCOS patients, the insulin-sensitizing effects of both MI and DCI were tested in order to ameliorate symptoms and signs of this syndrome, including the possibility to restore patients' fertility. Accumulating evidence suggests that both isoforms of inositol are effective in improving ovarian function and metabolism in patients with PCOS, although MI showed the most marked effect on the metabolic profile, whereas DCI reduced hyperandrogenism better. The purpose of this review is to provide an update on inositol signaling and correlate data on biological functions of these multifaceted molecules, in view of a rational use for the therapy in women with PCOS.

Citing Articles

[Polycystic ovary syndrome: new and promising treatment methods].

Gasieva D, Sheremetyeva E, Kalashnikova M, Dzgoeva F, Alborova E Probl Endokrinol (Mosk). 2024; 70(4):103-113.

PMID: 39302870 PMC: 11551798. DOI: 10.14341/probl13400.

Validation of the follicular and ovarian thresholds by an 18-MHz ultrasound imaging in polycystic ovary syndrome: a pilot cutoff for North African patients.

Ach T, Guesmi A, Kalboussi M, Ben Abdessalem F, Mraihi E, El Mhabrech H Ther Adv Reprod Health. 2024; 18:26334941241270372.

PMID: 39170801 PMC: 11337176. DOI: 10.1177/26334941241270372.

Causal effects of genetically determined metabolites on androgenetic alopecia: A two-sample Mendelian randomization analysis.

Du Y, Lu C, Bi L, Wang C, Zhao M, Ding Y Skin Res Technol. 2024; 30(5):e13732.

PMID: 38747971 PMC: 11095465. DOI: 10.1111/srt.13732.

Gestational testosterone excess early to mid-pregnancy disrupts maternal lipid homeostasis and activates biosynthesis of phosphoinositides and phosphatidylethanolamines in sheep.

Saadat N, Pallas B, Ciarelli J, Vyas A, Padmanabhan V Sci Rep. 2024; 14(1):6230.

PMID: 38486090 PMC: 10940674. DOI: 10.1038/s41598-024-56886-6.

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression.

Zhou J, Mo H, Feng Q, Li L, La J J Ovarian Res. 2023; 16(1):188.

PMID: 37689737 PMC: 10493025. DOI: 10.1186/s13048-023-01263-6.

References

Goud P, Goud A, Leybaert L, Van Oostveldt P, Mikoshiba K, Diamond M . Inositol 1,4,5-trisphosphate receptor function in human oocytes: calcium responses and oocyte activation-related phenomena induced by photolytic release of InsP(3) are blocked by a specific antibody to the type I receptor. Mol Hum Reprod. 2002; 8(10):912-8. DOI: 10.1093/molehr/8.10.912. View

Schuring A, Schulte N, Sonntag B, Kiesel L . Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch. 2008; 48(1):9-15. DOI: 10.1159/000111465. View

Myers Jr M, White M . The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes. 1993; 42(5):643-50. DOI: 10.2337/diab.42.5.643. View

Larner J, Huang L, Schwartz C, Oswald A, Shen T, Kinter M . Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun. 1988; 151(3):1416-26. DOI: 10.1016/s0006-291x(88)80520-5. View

Franks S . Polycystic ovary syndrome. N Engl J Med. 1995; 333(13):853-61. DOI: 10.1056/NEJM199509283331307. View

Carlomagno G, Unfer V, Roseff S . The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011; 95(8):2515-6. DOI: 10.1016/j.fertnstert.2011.05.027. View

Minozzi M, Nordio M, Pajalich R . The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013; 17(4):537-40. View

Baillargeon J, Diamanti-Kandarakis E, Ostlund Jr R, Apridonidze T, Iuorno M, Nestler J . Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006; 29(2):300-5. DOI: 10.2337/diacare.29.02.06.dc05-1070. View

Facchinetti F, Bizzarri M, Benvenga S, DAnna R, Lanzone A, Soulage C . Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015; 195:72-76. DOI: 10.1016/j.ejogrb.2015.09.024. View

10.

Yildirim B, Sabir N, Kaleli B . Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003; 79(6):1358-64. DOI: 10.1016/s0015-0282(03)00265-6. View

11.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2008; 91(2):456-88. DOI: 10.1016/j.fertnstert.2008.06.035. View

12.

Pizzo A, Lagana A, Barbaro L . Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2013; 30(3):205-8. DOI: 10.3109/09513590.2013.860120. View

13.

Graf M, Richards C, Brown V, Meissner L, Dunaif A . The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol (Oxf). 1990; 33(1):119-31. DOI: 10.1111/j.1365-2265.1990.tb00472.x. View

14.

Dresner A, Laurent D, Marcucci M, Griffin M, Dufour S, Cline G . Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999; 103(2):253-9. PMC: 407880. DOI: 10.1172/JCI5001. View

15.

Dekker J, Girman C, Rhodes T, Nijpels G, Stehouwer C, Bouter L . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112(5):666-73. DOI: 10.1161/CIRCULATIONAHA.104.516948. View

16.

. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2011; 27(1):14-24. DOI: 10.1093/humrep/der396. View

17.

Lagana A, Barbaro L, Pizzo A . Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2014; 291(5):1181-6. DOI: 10.1007/s00404-014-3552-6. View

18.

Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800. DOI: 10.1210/edrv.18.6.0318. View

19.

Larner J . D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002; 3(1):47-60. PMC: 2478565. DOI: 10.1080/15604280212528. View

20.

Coviello A, Legro R, Dunaif A . Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2005; 91(2):492-7. DOI: 10.1210/jc.2005-1666. View